These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 26038121)
1. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121 [TBL] [Abstract][Full Text] [Related]
2. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263 [TBL] [Abstract][Full Text] [Related]
3. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Morabito F; Cutrona G; Gentile M; Matis S; Todoerti K; Colombo M; Sonaglio C; Fabris S; Reverberi D; Megna M; Spriano M; Lucia E; Rossi E; Callea V; Mazzone C; Festini G; Zupo S; Molica S; Neri A; Ferrarini M Br J Haematol; 2009 Jun; 146(1):44-53. PubMed ID: 19438486 [TBL] [Abstract][Full Text] [Related]
4. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC; Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290 [TBL] [Abstract][Full Text] [Related]
5. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377 [TBL] [Abstract][Full Text] [Related]
6. ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status. Wiggers TG; Westra G; Westers TM; Abbes AP; Strunk A; Kuiper-Kramer E; Poddighe P; van de Loosdrecht AA; Chamuleau ME Cytometry B Clin Cytom; 2014 Jul; 86(4):280-7. PubMed ID: 24924909 [TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230 [TBL] [Abstract][Full Text] [Related]
8. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428 [TBL] [Abstract][Full Text] [Related]
9. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019 [TBL] [Abstract][Full Text] [Related]
10. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Adams RL; Cheung C; Banh R; Saal R; Cross D; Gill D; Self M; Klein K; Mollee P Cytometry B Clin Cytom; 2014 Mar; 86(2):80-90. PubMed ID: 24127306 [TBL] [Abstract][Full Text] [Related]
12. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis. Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470 [TBL] [Abstract][Full Text] [Related]
13. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492 [TBL] [Abstract][Full Text] [Related]
14. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482 [TBL] [Abstract][Full Text] [Related]
15. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778 [TBL] [Abstract][Full Text] [Related]
16. Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia. Wang YH; Zou ZJ; Liu L; Zhang LN; Fang C; Zhu DX; Fan L; Li JY; Xu W J Cancer Res Clin Oncol; 2012 Jun; 138(6):1011-7. PubMed ID: 22362302 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Letestu R; Rawstron A; Ghia P; Villamor N; Boeckx N; Boettcher S; Buhl AM; Duerig J; Ibbotson R; Kroeber A; Langerak A; Le Garff-Tavernier M; Mockridge I; Morilla A; Padmore R; Rassenti L; Ritgen M; Shehata M; Smolewski P; Staib P; Ticchioni M; Walker C; Ajchenbaum-Cymbalista F Cytometry B Clin Cytom; 2006 Jul; 70(4):309-14. PubMed ID: 16906588 [TBL] [Abstract][Full Text] [Related]
18. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status. Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia. Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526 [TBL] [Abstract][Full Text] [Related]